ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0962

Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial

Saloua Afilal1, Safaa Fellous1, Ilham Aachari1, Redouane Abouqal2, Ihsane Hmamouchi3, Nada Alami1, Latifa Tahiri1, Hanan Rkain1, Najia Hajjaj-Hassouni4 and Fadoua Allali1, 1Rheumatology B Department, El Ayachi Hospital, Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco., Rabat, Morocco, 2Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco., Rabat, Morocco, 3Temara Hospital, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRCE), Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco, Rabat, Morocco, 4Health Sciences College, International University of Rabat (UIR), Rabat, Morocco

Meeting: ACR Convergence 2020

Keywords: Back pain, Randomized Trial

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Orthopedics, Low Back Pain, & Rehabilitation (0960–0964)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: Lumbar radicular pain is the most common chronic neuropathic pain syndrome. Antidepressants are highly recommended for neuropathic pain, but there is no evidence for their efficacy.

The aim of this double-blind, randomised, placebo-controlled trial is to determine whether clomipramine (an antidepressant) is more effective than placebo in reducing pain in individuals with resistant chronic lumbar radicular pain.

Methods: A double-blind, randomized, clinical trial. Sixty-two patients with resistant chronic lumbar radicular pain were included. (The sample size was calculated on the assumption that clomipramine would reduce the incidence of lumbar radicular pain of 35%, compared with placebo, with a two-sided test, an alpha level of 0.05, and a power of 85%). Patients were randomly allocated to receive either Clomipramine by slow intravenous infusion for 10 days in a hospital setting with progressively increasing doses, 25 mg on the first day, 50 mg on the second day and 75 mg on the third day until the tenth day, or placebo (500 ml of physiological serum a day). For both groups, paracetamol is added intravenously at a dose of 3g per day for ten days, Parecoxib for 3 days and ten sessions of lumbar spine rehabilitation including analgesic massage, muscle strengthening and joint maintenance. At the exit, clomipramine was relayed with 25 mg per day orally until the 90th day for clomipramine group, and paracetamol was authorized in both groups, in case of severe pain. The primary outcome was pain intensity, measured at baseline, 5th day, 10th day and 90th day using VAS pain (10 mm). Secondary outcome included DN4-questionnaire, lumbar radicular discomfort (VAS 10 mm), pain-free perimeter of walking (min), disability assessed using the Roland Morris Disability questionnaire and severity of mood symptoms assessed using the Hospital Anxiety and Depression scale (HAD), measured on days 0, 5, 10 and 90.

Results: 31 patients were assigned to the clomipramine group and 31 to the placebo group. There were no differences between the groups in baseline characteristics. Treatment by clomipramine had a significantly greater reduction in pain, discomfort and DN4 from the 5thday compared to the placebo (3,83 ± 1,63 vs 5,38 ± 1,11, p< 0.0001, 3,90 ± 1,85 vs 5,35 ± 1,45, p= 0.001, 1,87 ± 1,68 vs 3,09 ± 1,49, p= 0.004 respectively) with significant differences maintained until 90th day. There was a statistically significant improvement in pain-free walking distance and disability for the clomipramine group from the 10th day compared to placebo (38 ± 27,04 vs 24,35 ± 17,25, p = 0.02 and 7,61 ± 4,96 vs 11,70 ± 4,51, p=0.001, respectively) and that maintained until 90th day. However, there was no statistically significant differences in HAD between the 2 groups.

Conclusion: This double-blind, randomized, clinical trial shows that clomipramine is quickly effective and maintained over time in the management of resistant chronic lumbar radicular pain. It can therefore be part of the therapeutic arsenal in this sense.


Disclosure: S. Afilal, None; S. Fellous, None; I. Aachari, None; R. Abouqal, None; I. Hmamouchi, None; N. Alami, None; L. Tahiri, None; H. Rkain, None; N. Hajjaj-Hassouni, None; F. Allali, None.

To cite this abstract in AMA style:

Afilal S, Fellous S, Aachari I, Abouqal R, Hmamouchi I, Alami N, Tahiri L, Rkain H, Hajjaj-Hassouni N, Allali F. Efficacy of Clomipramine for Chronic Lumbar Radicular Pain a Randomized Clinical Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-clomipramine-for-chronic-lumbar-radicular-pain-a-randomized-clinical-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-clomipramine-for-chronic-lumbar-radicular-pain-a-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology